Second quarter results
Detrol, the anti-glaucoma agent Xalatan ($68 mil. in sales, up 92% in local currency), the low-molecular heparin Fragmin ($48 mil., up 21%), and the oncologic Camptosar ($44 mil., up 16%) helped the company post a 7% increase in sales (excluding currency) to $1.65 bil. for the quarter. Earnings grew 13% to $187 mil., excluding a $41 mil. after-tax charge related to the settlement of retail pharmacy prescription pricing litigation
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth